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Dyskeratosis congenita and the DNA damage response
Dyskeratosis congenita (DC) is an inherited disorder character-
ized by muco-cutaneous abnormalities consistent with a
premature ageing phenotype, bone marrow failure and
a predisposition to cancer (Dokal, 2001). As well as serving as
a model of ageing in humans it is also a model disease for
telomeredysfunctionasitistheﬁrstdiseasethatisthoughttobe
caused by premature telomere shortening (Calado & Young,
2009; Bessler et al, 2010). Seven genetic subtypes have been
described, ﬁve of which have genetic lesions in components
(dyskerin, TERC, TERT, NOP10 and NHP2) belonging to the
telomerase holoenzyme (Heiss et al, 1998; Vulliamy et al, 2001,
2008; Armanios et al, 2005; Walne et al, 2007), which is
responsible for maintaining telomere length in certain tissues,
and one of which (TIN2) has a lesion in the telomere shelterin
complex (Savage et al, 2008), which is responsible for main-
taining the structural integrity of the telomere (de Lange, 2005).
While the disease was ﬁrst thought to be due to defective
ribosome biogenesis (Heiss et al, 1998; Luzzatto & Karadim-
itris, 1998) data published in the intervening years has heavily
implicated premature telomere shortening as the primary
cause of the pathology. Indeed DC patients, as a group, have
very short telomeres (Mitchell et al, 1999; Alter et al, 2007)
and the clinical phenotype is consistent with premature loss of
cells in tissues with high turnover such as the skin, gut and
bone marrow.
Recent studies have suggested that cells with DC-relevant
mutations have an increased DNA damage response that has
previously been overlooked and that this may play an
important role in disease pathology (Gu et al, 2008). However,
the current DNA damage studies have been carried out only in
a single cell type (ﬁbroblasts) with much of the work having
been done in mouse models (Gu et al, 2008; Vidal-Cardenas &
Greider, 2010). The only analysis of characterized DC patient
cells was in a single family with a TERC mutation (Westin
et al, 2010). We therefore wanted to determine how prominent
this potential mechanism might be in DC pathophysiology.
In this study we analysed primary human tissue exclusively,
with the aim of avoiding, wherever possible, artefacts from
transformation or genetic modiﬁcation and potential differ-
ences between human cells and animal models. We obtained
cells from patients with mutations in the telomerase genes
DKC1 (the gene encoding dyskerin, a telomerase structural
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Summary
Dyskeratosis congenita (DC) is a heterogeneous bone marrow failure
disorder with known mutations in components of telomerase and telomere
shelterin. Recent work in a mouse model with a dyskerin mutation has
implicated an increased DNA damage response as part of the cellular
pathology, while mouse models with Terc and Tert mutations displayed a
normal response. To clarify how these contradictory results might apply to
DC pathology in humans, we studied the cellular phenotype in primary cells
from DC patients of several genetic subtypes, focussing on T lymphocytes to
remain close to the haematopoietic system. We observed novel cell cycle
abnormalities in conjunction with impaired growth and an increase in
apoptosis. Using ﬂow cytometry and confocal microscopy we examined
induction of the DNA damage proteins c-H2AX and 53BP1 and the cell cycle
protein TP53 (p53). We found an increase in damage foci at telomeres in
lymphocytes and an increase in the basal level of DNA damage in ﬁbroblasts,
but crucially no increased response to DNA damaging agents in either cell
type. As the response to induced DNA damage was normal and levels of
global DNA damage were inconsistent between cell types, DNA damage may
contribute differently to the pathology in different tissues.
Keywords: cell cycle, DNA damage, dyskeratosis congenita, lymphocytes,
telomeres.
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TERT (the telomerase reverse transcriptase), which collectively
constitute the majority of genetically characterized DC cases.
As bone marrow failure is the cause of mortality in approx-
imately 80% of DC cases (Kirwan & Dokal, 2009) we focussed
the majority of our analyses on T lymphocytes as these are cells
of the haematopoietic system. We also studied ﬁbroblasts in
order to compare our data with the published literature.
While our data conﬁrm that cell growth and survival are
impaired and that apoptosis is increased, we also uncovered
novelcellcycleabnormalities withfewerDCcellsinthedividing
S and G2 phases and more in the senescent/quiescent G0 phase.
Extensive analysis of the DNA damage response revealed
increased basal levels of DNA damage in ﬁbroblasts and
increased damage at telomeres in lymphocytes but crucially,
the response tofreshlyinduced DNA damagewas not increased.
We therefore concluded that, while DNA damage is increased –
consistent with the accumulation of short or dysfunctional
telomeres – this is inconsistent between cell types and we found
no evidence that increased response to induced DNA damage is
responsible for the cellular or clinical phenotype.
Materials and methods
Patient T lymphocyte acquisition and tissue culture
Blood samples were obtained from patients and unaffected
controlvolunteersatBartsandTheLondonChildren’sHospital,
London with informed, written consent and research ethics
committee approval. T lymphocytes were separated using
lymphocyte separation medium (Lonza, Wokingham, UK)
and selected for by RosetteSep antibody cocktail (Stem Cell
Technologies, Grenoble, France) according to the manufac-
turer’sinstructions,washedtwicewithphosphatebufferedsaline
(PBS) and resuspended at 1Æ0 · 10
6 cells/ml in RPMI-1640
medium + 10% fetal calf serum (FCS; Invitrogen, Paisley, UK).
Purity of the isolated T lymphocytes was determined by ﬂow
cytometry using a monoclonal anti-human CD3e mouse IgG
conjugated to allophycocyanin (R&D Systems, Abingdon, UK)
according to the manufacturer’s instructions. Mitosis was
stimulated by the addition of 10 lg/ml of phytohaemagglutinin
(PHA; Roche Applied Science, Burgess Hill, UK). After 48 h the
medium was replaced with fresh RPMI containing 10 units/ml
of recombinant human interleukin 2 (Invitrogen). Cells were
counted on a NucleoCounter YC-100 automated cell counter
(ChaemoMetec, Allerod, Norway). Fibroblasts were cultured in
RPMI-1640 medium + 10% FCS. All three DC ﬁbroblasts
contained DKC1 mutations (c.106T>G/p.Phe36Val,
c.361A>G/p.Ser121Gly and c.1058C>T/p.Ala353Val).
Telomere length measurement
Telomere lengths were measured by Southern blot of genomic
DNA from peripheral blood leucocytes using a subtelomeric
probe, pTelBam8, as previously described (Notaro et al, 1997).
Cell cycle analysis
All ﬂow cytometry was conducted using an LSRII four laser
ﬂow cytometer (Becton Dickinson, UK, Ltd. (BD), Oxford,
UK). Apoptosis levels were determined using the Vibrant
Apoptosis Assay Kit#3 (Invitrogen) according to the manu-
facturer’s instructions before ﬂow cytometry. Brieﬂy, this
involved staining of nuclear DNA with propidium iodide (PI)
and co-staining of the apoptotic membrane marker phospha-
tidylserine with a ﬂuorescent annexin V conjugate.
G0/G1, S and G2M populations were determined using
standard methods. 0Æ2 · 10
6 cells were ﬁxed overnight in 70%
ethanol, washed twice in PBS and resuspended in 300 ll PBS
with 50 lg/ml PI and 200 lg/ml RNAse A. Cells were
incubated at 37 C for 30 min before being analysed on the
ﬂow cytometer. Cells were pulse-width gated to exclude
doublets.
G0 and G1 populations were determined using a method
modiﬁed from Ladd et al (1997). Brieﬂy, 0Æ2 · 10
6 cells were
washed twice in PBS and resuspended in 300 ll PBS with
10 lg/ml Hoescht 33342 and 0Æ5 lg/ml Pyronin Y. Cells were
incubated at 37 C for 45 min before being analysed on the
ﬂow cytometer. Cells were pulse-width gated to exclude
doublets.
DNA damage-associated c-H2AX and TP53 (p53)
analysis
To assay levels of c-H2AX and TP53 lymphocytes were
harvested 12 d after PHA stimulation. Cells were treated either
with the appropriate concentration of etoposide or an
equivalent volume of dimethyl sulfoxide (DMSO) carrier at
37 C then washed twice in PBS before being ﬁxed in 2%
paraformaldehyde and permeablized in PBS 1% Triton X-100.
Cells were washed once in PBS 0Æ1% Triton, resuspended in
500 ll PBS 0Æ1% Triton and incubated in the presence of
1:1000 dilution of anti-c-H2AX antibody (ab11174; Abcam,
Cambridge, UK) or 1:300 dilution of anti-TP53 antibody
(ab32509; Abcam) for 30 min in the dark. Cells were then
washed three times in PBS 0Æ1% Triton, resuspended in 500 ll
PBS 0Æ1% Triton and incubated in the presence of 0Æ5 lgo f
Alexa Fluor
  647 goat anti-rabbit IgG (Invitrogen) for 30 min
in the dark. Cells were washed three times in PBS 0Æ1% Triton
and resuspended in 300 ll PBS 0Æ1% Triton + 1 lg/ml
4¢,6-diamidino-2-phenylindole (DAPI) to counter-stain nuclei
for cell cycle determination before analysis by ﬂow cytometry.
Cells were pulse-width gated to exclude doublets.
Immunocytoﬂuorescence confocal microscopy
Cells were treated either with 5 lmol/l etoposide or an
equivalent volume of DMSO carrier for 30 min at 37 C then
washed twice in PBS 1% bovine serum albumin before being
allowed to gravity settle onto glass slides. Cells were ﬁxed in
4% paraformaldehyde for 15 min and permeablized with 0Æ5%
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rabbit anti-53BP1 antibody (ab21083; Abcam) and TRF1 was
labelled with mouse anti-TRF1 antibody (ab10579; Abcam).
Secondary antibodies used were Alexa Fluor
  555 donkey anti-
mouse IgG (A-31570; Invitrogen) and Alexa Fluor
  488 goat
anti-rabbit IgG (A-11008; Invitrogen). DNA was counter-
stained with DAPI. Slides were viewed on a Zeiss 510M
confocal microscope.
Statistical analyses
Data were analysed using a Student’s t-test with P values below
0Æ05 considered signiﬁcant and below 0Æ01 considered highly
signiﬁcant. All P values are indicated in the text.
Results
Patients
The patients in our cohort are detailed in Table I. T
lymphocytes were harvested from DC patients’ blood when
they attended our clinic. On each occasion T lymphocytes were
also acquired from a healthy donor and these were processed
and analysed alongside the patient sample to provide paired
controls. The purity of the isolated T lymphocytes was
determined to be 98Æ0±1 Æ4% by measuring CD3 expression
using ﬂow cytometry. The patients comprised ﬁve DKC1, six
TERC and two TERT mutations. Several of the TERC
mutations have previously been assayed for telomerase activity
in an in vitro ﬁbroblast line system using co-transfection of
plasmids bearing TERT and TERC with the mutations in
question and these results have been noted (Table I). There
were nine males, four females and the mean age (years) of the
group was 25 ± 3 SE (standard error). Of the controls, 10 were
male, three were female and the mean age was 37 ± 3 SE. It
was not possible to acquire an age- and sex-matched control
each time a sample was acquired owing to the availability of
suitable controls at the time of the clinic. The telomere length
(expressed as Dtel) was determined in the peripheral blood of
all but one of the DC patients and in every case telomeres were
shorter than normal. Seven were below the ﬁrst centile and a
further four were below the tenth (Table I). All of the patients
had one or more abnormal haematological value with the
exceptions of patients D2 and D4. Of the 13 DC patients, nine
had reduced haemoglobin levels, 10 had reduced platelet
counts (and generally were severely affected) and six were
lymphopenic. Interestingly, none were T lymphopenic.
DC lymphocytes have impaired growth characteristics,
increased apoptosis and abnormal cell cycle proﬁles
Despite the fact that none of the patients in our cohort were T
lymphopenic, culture of these lymphocytes after stimulation
with the mitogen PHA showed a clear and progressive
impairment of growth relative to normal controls (Fig 1A,
B). This was accompanied by a persistently elevated level of
apoptosis (1Æ5–2-fold higher, P <0 Æ01 by day 28) (Fig 1C, D),
a ﬁnding that has been demonstrated previously in a single
large family with a TERC mutation (Knudson et al, 2005). Cell
cycle analyses of cellular DNA content demonstrated a small
but statistically signiﬁcant increase in the proportion of DC
cells in the G0/G1 phase at days 7 and 21 (P <0 Æ01 at day 21)
(Fig 2A, B). In conjunction with this there was a general
reduction in the proportion of cells in the S phase (P =0 Æ02 at
days 14 and 21) and G2/M phase (P =0 Æ02 by day 28) (Fig 2C,
D, respectively). A more detailed analysis of cellular DNA and
RNA content showed that a higher proportion of DC
lymphocytes were in the RNA-low G0 phase (P =0 Æ02 by
day 28) (Fig 2E–G), consistent with a more senescent popu-
lation. These data suggest that a combination of increased
apoptosis and senescence contribute to growth impairment in
DC lymphocytes.
The DNA damage response is not up-regulated in DC
lymphocytes
Recent studies have implicated an abnormal DNA damage
response in the pathology of DC in ﬁbroblasts from both
humans and mouse models (Gu et al, 2008; Westin et al,
2010). We wanted to determine if this might play a role in the
impaired growth phenotype of DC lymphocytes. Previous
studies have used phosphorylation of histone protein H2AX to
c-H2AX as an early marker of the cellular response to DNA
damage. We therefore measured the levels of c-H2AX in DC
lymphocytes relative to controls using ﬂow cytometry
(Fig 3A). Steady state levels were measured along with the
level after induction by a 30-min exposure to 350 lmol/l
etoposide, a chemical known to cause double-strand DNA
breaks (Fig 3B).
The level of steady-state c-H2AX was not signiﬁcantly
different between controls and DC cells (P =0 Æ31). As
expected, exposure to etoposide induced an increase in
c-H2AX expression in both control and DC cells. However,
there was no signiﬁcant difference between controls and DC
cells (P =0 Æ88), nor was there a signiﬁcant difference in the
level of induction (i.e. the fold-increase in c-H2AX level after
exposure to etoposide), which was around 2Æ5-fold in these
samples (P =0 Æ35) (Fig 3C).
We considered that the concentration of etoposide used
might be so high that no discrimination between DC and
control would be possible. To determine whether this was
the case we repeated the assays using a dose range from
1 lmol/l to 1 mmol/l. As expected, there was a dose-
dependent response to etoposide exposure (Fig 4A). The
response was broadly similar across the dose range used but,
if anything, the level of expression was 10–15% lower in the
DC lymphocytes, although this did not reach statistical
signiﬁcance (Fig 4B).
We also considered that c-H2AX expression or etoposide
function might be cell-cycle dependent. As cellular DNA was
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speciﬁcally for populations in the G0/G1, S and G2/M phases of
the cell cycle (Fig 4C) and repeat the analysis of c-H2AX
expression (Fig 4D). We found that the pattern remained
similar for all phases but the reduction in c-H2AX expression
in DC samples was statistically signiﬁcant in both the S and G2/
M phases (P values <0Æ03 for all dosages), conﬁrming a cell
cycle-dependent effect.
(A)
(B)
(C)
(D)
Fig 1. T lymphocytes from DC patients show impaired growth and increased apoptosis. (A) Cell numbers counted every 7 d in T lymphocyte
cultures. 1 · 10
6 cells were plated at day 0 and stimulated with PHA for 48 h. Cells were subsequently cultured in interleukin-2 supplemented
medium. (B) DC lymphocyte cell numbers expressed as a percentage of control cell numbers (control n = 10) show an increasing growth deﬁcit over
the culture period. (C) Propidium iodide and annexin V co-staining of lymphocytes as measured by ﬂow cytometry using sample D1 as an example.
On the left is the control sample and on the right the patient sample. (D) A higher proportion of DC lymphocytes (around twofold higher than
controls) were apoptotic over 49 d in culture. Error bars represent the standard error from six patient sample measurements (four TERC, two DKC1)
against six paired controls.
(A) (B)
(E)
(C)
(F)
(D)
(G)
Fig 2. Cell cycle abnormalities in DC lymphocytes after mitogenic stimulation (A) Nuclear staining of lymphocytes with propidium iodide
as measured by ﬂow cytometry. The phases of the cell cycle are marked. (B) More DC lymphocytes are in the G0/G1 phase compared to
controls. (C) Fewer DC lymphocytes are in the S phase compared to controls. (D) Fewer DC lymphocytes are in the G2/M phase compared to
controls. (E) Co-staining of lymphocyte DNA with Hoescht 33342 and RNA with pyronin Y as measured by ﬂow cytometry using sample D1 as an
example. On the left is the control and on the right the patient sample. The phases of the cell cycle are marked. (F) More DC lymphocytes are in the
G0 phase compared to controls. (G) Fewer DC lymphocytes are in the G1 phase compared to controls. All graphs express fold difference to control
samples. Error bars represent the standard error from six patient sample measurements (four TERC, two DKC1) against six paired controls.
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ATM-TP53/CDKN1A (p21)-dependent DNA damage check-
point response (Shiloh, 2003) and TP53 expression has also
been shown to be upregulated in mouse embryonic ﬁbroblasts
with a Dkc1 mutation after etoposide treatment (Gu et al,
2008). We therefore measured TP53 by ﬂow cytometry after
6 h exposure to etoposide over a range of 1–100 lmol/l. As
expected, both DC and control cells showed a dose response
(Fig 5A) but again, TP53 levels were, if anything, lower in the
DC lymphocytes (Fig 5B), however this was only signiﬁcant at
concentrations of 10 lmol/l and above (P <0 Æ03). These
results suggest that the global response to DNA damage is not
elevated in DC lymphocytes and in fact may be slightly
reduced.
DC lymphocytes have increased DNA damage at telomeres
DNA damage response assays are more usually performed
using microscopic quantiﬁcation of DNA damage foci. To
validate our ﬂow cytometry protocol we therefore labelled DC
and control cells for 53BP1, a protein known to co-localize
with c-H2AX to sites of DNA damage (Nelms et al, 1998) and
which gives more easily quantiﬁable results in microscopic
assays (Takai et al, 2003) (Fig 6A). Two DC samples were
compared to a control sample and 50 nuclei were counted in
each. We found no signiﬁcant difference in the average
number of 53BP1 foci per cell between controls and DC
patients either with or without etoposide exposure (P >0 Æ1i n
all cases) (Fig 6B), consistent with our ﬂow cytometry data
obtained with a single etoposide dose.
DNA damage at telomeres has been demonstrated in
ﬁbroblasts from both human DC patients and mouse models
(A)
(B) (C)
Fig 3. The DNA damage response is not up-regulated in T lympho-
cytes from our DC cohort. (A) DNA damage associated histone protein
c-H2AX expression as measured by ﬂow cytometry. Fluorescence is
measured in the absence of antibodies to determine levels of auto-
ﬂuorescence (blank). Fluorescence in the presence of ﬂuorescently-
labelled secondary antibody only is regarded as non-speciﬁc and is
subtracted from all subsequent measurements. Fluorescence in the
presence of primary (anti-c-H2AX) antibody plus secondary is
considered speciﬁc due to the presence of c-H2AX. Incubation with
etoposide causes a net increase in median ﬂuorescence due to increased
activation of H2AX to c-H2AX. (B) Relative expression of c-H2AX in
DC lymphocytes compared to controls both with and without
350 lmol/l etoposide exposure shows no signiﬁcant difference. (C)
Fold induction of c-H2AX expression in DC lymphocytes is not sig-
niﬁcantly different to controls. Error bars represent the standard error
from six DC samples (three TERC, two DKC1, one TERT) against six
paired controls.
(A) (B)
(C) (D)
Fig 4. c-H2AX expression in T lymphocytes assayed in detail across a
range of etoposide doses and cell cycle populations. (A) Example of a
c-H2AX dose-response curve for etoposide exposure showing a control
sample and a DC sample in the same assay. (B) c-H2AX expression of
nine DC samples (ﬁve TERC, three DKC1 and one TERT) normalized
to seven paired controls. (C) After acquisition of whole cells (upper
panel) DAPI staining of the nuclei allows exclusion of doublets (middle
panel) and cells in different phases of the cell cycle can be speciﬁcally
gated (lower panel). (D) Dose-response curves showing c-H2AX
expression in different phases of the cell cycle.
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2010; Vidal-Cardenas & Greider, 2010). To determine whether
this was relevant to DC lymphocytes we co-labelled 53BP1 and
the shelterin protein TRF1 and used confocal microscopy to
determine the extent of co-localization in DNA damage
complexes known as telomere dysfunction-induced foci (TIFs)
(Takai et al, 2003). Although the number of TIFs was low in
both the control and DC samples, there was a signiﬁcant
increase in the number of cells with TIFs and the numbers of
TIFs per cell in the DC samples (P <0 Æ01 in both cases)
(Fig 6C). Interestingly, exposure to etoposide did not signif-
icantly affect the number of TIFs either in control or DC
samples (P remained below 0Æ01 vs. control).
These data corroborate the ﬂow cytometry results and
conﬁrm that there is no global increase in DNA damage in DC
lymphocytes, and no increased response to DNA damaging
agents. However, they do demonstrate that there is a small but
signiﬁcant increase in DNA damage at telomeres.
Steady-state DNA damage is elevated in DC ﬁbroblasts
but the DNA damage response is normal
As previous DNA damage work has been carried out
exclusively on ﬁbroblasts we considered that there might be
cell type-speciﬁc effects at play. We therefore performed ﬂow
cytometric analysis of c-H2AX in DC ﬁbroblasts. We used a
single dose of etoposide because it is difﬁcult to grow
sufﬁcient numbers of ﬁbroblasts for a dose-response curve
assay. Unlike the T lymphocytes, the DC ﬁbroblasts showed
a marked and signiﬁcant increase in steady-state c-H2AX
level of around 75% compared to controls (Fig 7A)
(P =0 Æ04). However after etoposide treatment, although
there was still a higher level of c-H2AX in the DC cells,
signiﬁcance was lost (P =0 Æ31). The level of induction on
exposure to etoposide was similar to controls at around 1Æ5-
fold (Fig 7B) and was not signiﬁcantly different (P =0 Æ08).
These data indicate that DC ﬁbroblasts do have more
accumulated DNA damage than normal ﬁbroblasts but their
response to DNA damaging agents is normal.
Discussion
This study demonstrated abnormalities in growth, cell cycle
proﬁle and DNA damage in cells from DC patients. The cells
studied were all genetically unmanipulated, primary tissues
and represented three genetic subtypes of the disease.
The majority of published work on DC in humans has
suggested that an inability to maintain telomeres, either by a
dysfunction in the telomerase enzyme or by structural or
mechanistic dysfunction at the telomere itself, results in
premature apoptosis or senescence. Indeed, the presence of a
short telomere is labelled as DNA damage by the normal
cellular response which includes the formation of c-H2AX-
and 53BP1-containing foci (d’Adda di Fagagna et al, 2003).
However, short telomeres have often not been determined as
the primary cause of pathology in studies of mouse models of
DC (He et al, 2002; Ruggero et al, 2003; Mochizuki et al,
2004), perhaps highlighting inherent differences in mouse and
human cell biology.
Recent work in ﬁbroblasts from both mouse models and
human tissues has suggested that an increase in the DNA
damage response may contribute to the disease pathology. This
has been demonstrated in mouse embryonic ﬁbroblasts with a
Dkc1 mutation by exposure to etoposide (Gu et al, 2008). In
human ﬁbroblasts with a TERC mutation increased DNA
damage, similar to that observed in our ﬁbroblasts, was
suggested to activate TP53 and thereby sensitize the cells to
reactive oxygen species (Westin et al, 2010). By studying both
ﬁbroblasts and lymphocytes we have shown that an increase in
global DNA damage is not a consistent feature of tissues from
DC patients. Further, by assessing the level of DNA damage
before and after exposure to etoposide we have demonstrated
that the response to DNA damage is not elevated and may, in
fact, be slightly lower in some DC cells. If cells were continually
and excessively activating their DNA damage response then
one would also expect an accumulation in the G2/M phase as
cells that were in the process of growth and division and have
accumulated damage foci run up against the G2/M checkpoint,
a situation commonly observed in lymphocytes from Fanconi
(A) (B)
Fig 5. Expression of TP53 in lymphocytes after 6 h of etoposide exposure across a range of concentrations. (A) Example showing that T lymphocytes
show a dose-response in TP53 expression after etoposide treatment. (B) There is no increase in TP53 expression in DC cells (one TERC, one TERT)
compared to two paired controls.
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Seyschab et al, 1995). Instead we observed a reduction in the S
and G2/M phase populations and a concomitant increase in the
G0/G1 population consistent with cells containing short
telomeres being unable to cycle out of G1.
The role of the DNA damage response in DC is not
universally agreed upon. One study in Terc and Tert knockout
mouse cells, contrary to other published reports of mouse Dkc1
mutation, suggested that the number of DNA damage foci and
the amount of DNA damage associated protein induction was
the same as or lower than in normal mouse cells (Vidal-
Cardenas & Greider, 2010). The effect on TP53 regulation is
also unclear. While one study observed an increase in TP53
expression in mouse Dkc1 mutant cells after etoposide
exposure (Gu et al, 2008), another reported a decrease, both
in mouse cells and human B lymphocyte lines bearing dyskerin
mutations, due to an impairment in internal ribosome entry
site (IRES)-mediated TP53 translation (Bellodi et al, 2010).
Looking back to much earlier work on the exposure of human
DC lymphocytes and ﬁbroblasts to clastogens, no signiﬁcant
difference was found compared to normal cells in terms of
survival or chromosomal breakage (Dokal et al, 1992). If the
(A)
(B)
(C)
Fig 6. Confocal microscopy showing DNA damage foci in T lymphocytes. (A) Three example images showing nuclei stained with DAPI and labelled
for TRF1 telomeric protein, 53BP1 DNA damage protein and a merged image showing 53BP1 colocalizing with telomeres at telomere induced
damage foci (TIFs). (B) The number of 53BP1 DNA damage foci per nucleus is similar in a control sample and in two DC samples. (C) There is a
small but signiﬁcant increase in the number of TIFs in the DC lymphocytes. In all cases 50 nuclei were counted.
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then this would affect survival after exposure to DNA
damaging agents. However it remains at least possible that,
because telomeres are already short in DC patients, the
pre-existing disease context could potentially mask some of the
effects that are observed in model systems.
Clearly, there is an abnormality in the basal level of DNA
damage in the ﬁbroblasts we studied and this is consistent with
other published reports. This may well represent an accumu-
lation of damage in cells that would be consistent with the
accumulation of senescent ﬁbroblasts with short or dysfunc-
tional telomeres over time in culture. That we did not observe
it in lymphocytes suggests that it is not a consistent feature of
the disease across tissues. This is in contrast to Fanconi
anaemia, in which chromosomal breakage is a consistent
feature in both lymphocytes and ﬁbroblasts (Auerbach, 1993).
The growth curves for T lymphocytes (Fig 1A) demonstrate a
rapid clearance of dead cells from culture, which may explain
why such an accumulation does not occur with this cell type.
On the other hand, we did observe a small but signiﬁcant
increase in the number of damage foci at telomeres in
lymphocytes and again this is consistent with the presence of
short or dysfunctional telomeres. Nonetheless, both cell types
responded to etoposide exposure in a similar fashion to
normal cells, suggesting that their DNA damage response
machinery is intact.
While we contend that the role of DNA damage is secondary
to telomere shortening in DC, we do not rule out the
possibility that it contributes to pathology. Further to this,
although features of increased DNA damage response are not
displayed in the genetic subtypes of lymphocytes we have
studied, additional work is necessary to clarify the situation in
other subtypes. In particular, DC caused by mutations in the
shelterin component TIN2 would be worthy of particular
attention since expression of truncated forms of TIN2 (Kim
et al, 2004) and inactivation of another shelterin component
TRF2 (Takai et al, 2003) have been shown to result in the
accumulation of c-H2AX-containing DNA damage foci at
telomeres in cell lines. There are also the approximately 50% of
genetically uncharacterized cases to consider, whose genetic
and molecular mechanisms remain unknown.
Overall, our study points to short or dysfunctional telomeres
as the primary cause of pathology in human cases of DC in the
context of mutations in DKC1, TERC and TERT. While the
accumulation of DNA damage may contribute to the pathol-
ogy in some tissues, a dysfunctional DNA damage response is
unlikely to play a primary role in the overall clinical phenotype
in these individuals.
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